ATE283047T1 - Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose - Google Patents
Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple skleroseInfo
- Publication number
- ATE283047T1 ATE283047T1 AT98936715T AT98936715T ATE283047T1 AT E283047 T1 ATE283047 T1 AT E283047T1 AT 98936715 T AT98936715 T AT 98936715T AT 98936715 T AT98936715 T AT 98936715T AT E283047 T1 ATE283047 T1 AT E283047T1
- Authority
- AT
- Austria
- Prior art keywords
- ibudilast
- multiple sclerosis
- treatment
- production
- medicinal product
- Prior art date
Links
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002491 ibudilast Drugs 0.000 title abstract 3
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 3
- 229940126601 medicinal product Drugs 0.000 title 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Forklifts And Lifting Vehicles (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP1998/003548 WO2000009127A1 (en) | 1998-08-10 | 1998-08-10 | Remedies for multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE283047T1 true ATE283047T1 (de) | 2004-12-15 |
Family
ID=14208769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98936715T ATE283047T1 (de) | 1998-08-10 | 1998-08-10 | Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6395747B1 (de) |
| EP (1) | EP1106178B1 (de) |
| JP (1) | JP4828003B2 (de) |
| AT (1) | ATE283047T1 (de) |
| AU (1) | AU8562198A (de) |
| CA (1) | CA2339934C (de) |
| DE (1) | DE69827853T2 (de) |
| DK (1) | DK1106178T3 (de) |
| ES (1) | ES2231998T3 (de) |
| PT (1) | PT1106178E (de) |
| WO (1) | WO2000009127A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1570847B1 (de) | 2002-12-03 | 2012-04-25 | Kyorin Pharmaceutical Co., Ltd. | Phosphodiesterase 10a-hemmer zur behandlung der parkinson-krankheit, der huntington-krankheit und der schizophrenie |
| JP2007512337A (ja) * | 2003-11-21 | 2007-05-17 | コンビナトアールエックス インコーポレーティッド | 炎症性障害の治療のための方法および試薬 |
| US20060093578A1 (en) * | 2004-11-04 | 2006-05-04 | Kyorin Pharmaceutical Co., Ltd. | Method and composition for treating multiple sclerosis |
| WO2006063048A2 (en) * | 2004-12-06 | 2006-06-15 | Avigen, Inc. | Ibudilast for treating neuropathic pain and associated syndromes |
| KR100780479B1 (ko) | 2006-05-08 | 2007-11-28 | 윈셋파마 주식회사 | 이부딜라스트 함유 경구용 제제 및 이의 제조방법 |
| EP2026804A1 (de) * | 2006-05-31 | 2009-02-25 | Avigen, Inc. | Ibudilast zur hemmung der aktivität des makrophagen-migrationshemmungsfaktors |
| PL2131841T3 (pl) * | 2007-01-30 | 2013-03-29 | Avigen Inc | Sposoby leczenia bólu ostrego |
| US20080287402A1 (en) * | 2007-05-03 | 2008-11-20 | Johnson Kirk W | Use of a glial attenuator to prevent amplified pain responses caused by glial priming |
| CA2693697C (en) * | 2007-07-11 | 2017-07-25 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| EP3558301A4 (de) | 2016-12-22 | 2020-07-29 | MediciNova, Inc. | Verfahren zur behandlung von glioblastoma multiforme mit ibudilast |
| CA3090887A1 (en) * | 2018-02-12 | 2019-08-15 | Medicinova, Inc. | Methods of suppressing myeloid-derived suppressor cells in patients |
| CA3090884A1 (en) | 2018-02-12 | 2019-08-15 | Medicinova, Inc. | Methods and dosing regimens using ibudilast and a second agent for cancer therapy |
| CA3135420A1 (en) * | 2018-04-05 | 2019-10-10 | Universiteit Hasselt | Selective pde4d inhibitors against demyelinating diseases |
| EP3863628B1 (de) | 2018-10-09 | 2023-12-27 | MediciNova, Inc. | Kombination von ibudilast und interferon-beta und methoden zu deren verwendung |
| ES2970996T3 (es) | 2018-10-19 | 2024-06-03 | Medicinova Inc | Tratamiento de la lesión macular asociada a la esclerosis múltiple con ibudilast |
| WO2020251748A1 (en) * | 2019-06-11 | 2020-12-17 | Yale University | Novel treatment for wolfram syndrome |
| JP7652763B2 (ja) | 2019-09-23 | 2025-03-27 | メディシノバ・インコーポレイテッド | イブジラスト経口製剤およびその使用方法 |
| CN115335049A (zh) | 2020-04-06 | 2022-11-11 | 美迪诺亚公司 | 降低患者中巨噬细胞迁移抑制因子的血浆水平的方法 |
| CN116887829A (zh) | 2021-01-29 | 2023-10-13 | 美迪诺亚公司 | 治疗化学气体暴露的方法 |
| JP2024528731A (ja) | 2021-07-26 | 2024-07-30 | メディシノバ・インコーポレイテッド | 眼癌転移を予防するためのイブジラスト |
| CA3231869A1 (en) | 2021-09-21 | 2023-03-30 | Medicinova, Inc. | Ibudilast in combination therapy for use in the treatment of glioblastoma |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
| JP2025504984A (ja) | 2022-02-01 | 2025-02-19 | メディシノバ・インコーポレイテッド | Ｃｏｖｉｄ後症状の治療における使用のためのイブジラスト |
| US20240016729A1 (en) | 2022-07-13 | 2024-01-18 | Medicinova, Inc. | Injectable formulations of ibudilast |
| WO2026060180A1 (en) | 2024-09-11 | 2026-03-19 | Medicinova, Inc. | Modified release formulations of ibudilast |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672622A (en) * | 1994-04-21 | 1997-09-30 | Berlex Laboratories, Inc. | Treatment of multiple sclerosis |
| WO1996006843A1 (en) * | 1994-08-29 | 1996-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Novel naphthyridine derivative and medicinal composition thereof |
-
1998
- 1998-08-10 AU AU85621/98A patent/AU8562198A/en not_active Abandoned
- 1998-08-10 US US09/762,616 patent/US6395747B1/en not_active Expired - Lifetime
- 1998-08-10 JP JP53649998A patent/JP4828003B2/ja not_active Expired - Lifetime
- 1998-08-10 PT PT98936715T patent/PT1106178E/pt unknown
- 1998-08-10 DE DE69827853T patent/DE69827853T2/de not_active Expired - Lifetime
- 1998-08-10 DK DK98936715T patent/DK1106178T3/da active
- 1998-08-10 ES ES98936715T patent/ES2231998T3/es not_active Expired - Lifetime
- 1998-08-10 AT AT98936715T patent/ATE283047T1/de active
- 1998-08-10 CA CA002339934A patent/CA2339934C/en not_active Expired - Lifetime
- 1998-08-10 EP EP98936715A patent/EP1106178B1/de not_active Expired - Lifetime
- 1998-08-10 WO PCT/JP1998/003548 patent/WO2000009127A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP4828003B2 (ja) | 2011-11-30 |
| CA2339934C (en) | 2008-06-03 |
| US6395747B1 (en) | 2002-05-28 |
| WO2000009127A1 (en) | 2000-02-24 |
| AU8562198A (en) | 2000-03-06 |
| EP1106178A4 (de) | 2001-11-21 |
| DE69827853D1 (de) | 2004-12-30 |
| PT1106178E (pt) | 2005-02-28 |
| EP1106178B1 (de) | 2004-11-24 |
| DE69827853T2 (de) | 2005-12-08 |
| CA2339934A1 (en) | 2000-02-24 |
| DK1106178T3 (da) | 2005-02-28 |
| ES2231998T3 (es) | 2005-05-16 |
| EP1106178A1 (de) | 2001-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69827853D1 (de) | Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose | |
| DE3876877D1 (de) | Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus. | |
| DE69201948D1 (de) | Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b. | |
| ATE73331T1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| ATE332702T1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| NO870241D0 (no) | Hypoglykemiske tiazolidindioner. | |
| HUP9600448A2 (hu) | Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk | |
| ATE191849T1 (de) | Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst | |
| DE3879873D1 (de) | Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| DE59302501D1 (de) | Substituierte Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten | |
| ATE353645T1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| DE3873578D1 (de) | Verwendung von tetrahydrobenz(c,d)indol-6-carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden. | |
| ATE335487T1 (de) | Verwendung von pyridazino 4,5-(b)ö-indole-1- acetamide derivaten zur herstellung eines arzneimittels zur behandlung von durch periphere benzodiazepinrezeptoren-störungen verursachte krankheiten | |
| ATE74006T1 (de) | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken. | |
| ATE184788T1 (de) | Idebenone-haltige zusammensetzungen zur behandlung von m. alzheimer | |
| ATE85334T1 (de) | Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung. | |
| ATE135573T1 (de) | Verwendung von indazol-methoxyalkansäure zur herstellung eines arzneimittels zur behandlung von autoimmunkrankheiten | |
| ATE157871T1 (de) | Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind | |
| TNSN97143A1 (fr) | Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant | |
| KR880009957A (ko) | 알킬-치환된 n-벤조피라닐락탐, 이의 제조방법, 이의 용도 및 이들 화합물을 기본으로 하는 약제학적 제제 | |
| DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| ATE169635T1 (de) | Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen | |
| ATE110568T1 (de) | Pharmazeutisches präparat zur behandlung des katarakts. | |
| KR950032191A (ko) | 사이클로헥산 유도체, 이의 제조방법 및 질병을 치료하기 위한 화합물의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1106178 Country of ref document: EP |